Research In Motion Limited Message Board

As a market maker and a major (maybe the most significant short seller), Pacific Crest Security has been suspected for manipulating BBRY stock price at the cost of the company and the vast majority of shareholders for its own gain. It issued very timely "research reports" with all subjective speculation as support to manipulate the stock price for many times in the past several months.

If this is not a criminal act, I am wondering what could be called a criminal act. SEC and other authorities need to act swiftly.

Settlement Date Short Interest Avg Daily Share Volume Days To Cover
5/31/2013 8,388,313 1,854,881 4.522292
5/15/2013 7,776,374 825,948 9.415089

Pity of all the shorted shares, and more pitiful of all those who followed shorts by selling own shares!

Settlement Date Short Interest Avg Daily Share Volume Days To Cover
5/31/2013 171,313,332 18,306,433 9.358095
5/15/2013 170,632,578 29,749,364 5.735671

It seems after 31 May shorts may have piled significantly more shorted shares on the base of 31 May number of 171 millions. My estimation would be around 175 ~ 180 millions.

I smell the smoke preceding the open fire that will burn shorts once for all!

Oncothyreon Inc . (NASDAQ:ONTY): Lampert Mark N (10% Owner) purchased 82,915 shares at a price of $1.78.

Oncothyreon Inc., is a clinical-stage biopharmaceutical company, which is focused on the development of therapeutic products for the treatment of cancer.

General trends: 1) In the past, everyone knows, and no repeat here; 2) At present and in the near future, Blackberry is up, up and up while Apple and Samsung are down, down, and down with Nokia struggling to hang on. Oh, well shorts have rights to dispute the above, but let us longs and shorts look at some fact as of 09 June 2013:

Blackberry Market Cap 7.14B
Nokia Corporation Market Cap 13.14B
Apple Inc. Market Cap 414.71B
Samsung Market Cap 217 billion

Which company has the most potential?

Personally, bbry having not yet traded in at least $20 a piece is out of my comprehension. I support my view by continually add to my long position.

But, don't get me wrong, I have enough patience, no matter it will be June 2013, or June 2014 or even June 2016 for the market to fully appreciate Blackberry's potential.

He is supposed to be everywhere reporting biotech news, and yes he did once on the recently released START trial abstract, releasing a pathetic twisted piece late in the evening (He must have been called to his duty overtime by hedge fund and must have been paid dearly for that pathetic). Okay, I take that, AF.

So why after ASCO, all are still strangely quiet from the media. Well, I guess this is due to two things: 1) Merck KGaA does not want it to be messed up with its discussing with FDA, and European counterpart, etc., but did you think Merck KGaA does this due to its intention to continue a trial and start a new trial of BLP25 alone? That would be unbelievable, so It must be that it have involved "potential approval" in its discussion with FDA, etc in a whatever form; 2) Hedge funds have always been stupid and lagged behind than some sentry and smart retail investors (for example in the case of ARNA, and now BBRY), and they are now quietly collecting shares, "shh, keep quiet AF can you, I am done yet)! So the AF, and the like have pretended that nothing has happened in the field of fighting the most deadly cancer in the planet!

Expect to see a crooked trading pattern for some time ahead.

BlackBerry's New Lawyer Is Getting Busy
By Hugo Miller - Jun 7, 2013 6:06 AM ET from Bloomberg

Steve Zipperstein prosecuted failed savings-and-loan associations in the 1980s and investigated the government's siege of the Branch Davidian compound in Waco, Texas, in the '90s. Now the battle-hardened lawyer has joined Canadian smartphone maker BlackBerry to fight its critics.
Zipperstein, who turns 54 this month, was lured out of retirement in Santa Barbara, California, last spring year by an offer to become BlackBerry's chief legal officer. He joined the Waterloo, Ontario-based company in July to handle everything from patent disputes to privacy issues, and says his time as a Justice Department lawyer and federal prosecutor in Los Angeles will serve him well in defending BlackBerry's interests.
"I was really blessed to be able to combine jury trial courtroom experience with inside-the-Beltway Washington political policy experience," Zipperstein said in an interview.
After years of market-share losses, BlackBerry is trying to stem a customer exodus to Google's Android and Apple's iOS, and the company's taking a more assertive legal approach to disputes. That includes challenging analysts who publish reports that BlackBerry says are untrue and lobbying for legislation to thwart companies derided as patent trolls, which obtain patents to demand royalties rather than making their own products.
One of Zipperstein's targets: Detwiler Fenton & Co., a Boston-based financial-services firm. Detwiler said in an April report that return rates of the new BlackBerry Z10 were unusually high and in some cases exceeded sales of the phone.
It was a charge that BlackBerry and Zipperstein refused to let stand unchallenged. The company asked both the U.S. Securities and Exchange Commission and the Ontario Securities Commission to investigate the report. Zipperstein at the time called it either "a gross misreading of the data or a willful manipulation." BlackBerry's stock fell almost 8 percent on April 11 after the Detwiler report appeared.
"Everyone is entitled to their opinion," Zipperstein said. "It was characterized as a statement of actual fact, and it was wrong."
Zipperstein declined to discuss where the investigations now stand, as did representatives from the SEC and the Ontario Securities Commission. Neither Anne Buckley, Detwiler Fenton's chief compliance officer, nor her colleague Steve Abbiuso returned responded to messages seeking comment.
Zipperstein's response to Detwiler Fenton was very much in character, said William Petersen, general counsel at Verizon Wireless, the largest U.S. wireless carrier. Zipperstein worked as Verizon's general counsel from 2003 until he retired in 2011.
"As a former federal prosecutor and investigator, he approached the job very creatively and aggressively," Petersen said in an interview. "He never wanted Verizon to be on the defensive, and that really helped."
Zipperstein also backs U.S. legislation that would force plaintiffs in patent litigation to pay the costs of the defendant, an attempt to dissuade frivolous lawsuits.
"For far too long, that conduct has gone on unchallenged," he said.
A week after Zipperstein joined the company in July, a federal jury awarded Mformation Technologies $147.2 million in a patent-infringement case against BlackBerry. Zipperstein went back to the judge to make the argument that Mformation had failed to meet the burden of proof. Six weeks later, the trial judge overturned the verdict and threw it out.
Mformation appealed the decision in September. Stephanie Markham, a spokeswoman for the Edison, New Jersey-based company, didn't return respond to messages seeking comment.
"BlackBerry is no longer an easy target for patent lawsuits," Zipperstein said. "We're fighting back and we're going to continue to fight back."
--With assistance from Susan Decker in Washington

Since NSPIRE is allowed to be modified to enroll ONLY cCRT, I see significantly improved chance of submission and conditional approval of BLP25 in US, and EU.

If that turns out to be true, it will save hundreds of thousands of Stage III patients.

It is the right thing to do by FDA and EU authorities!

Longs it is beyond my comprehension why you cannot hold your shares at least up to $16?????

My comments in [ ]
"H. Jack West, MD
‏@JackWestMD
I'm impressed by that 10.2 mo improvement in median OS in subset of 800 pts who received BLP-25 after concurrent chemo/RT #ASCO13
Reply Retweet Favorite More
1 [So apparently he changed his usual doomed opinion towards BLP25, and he was impressed]
RETWEET
8:17 AM - 4 Jun 13
Colfax ‏@ColfaxCapital 58m
@JackWestMD But they cannot file w regulators based on that data; so, more trials... PD-1 will make this irrelevant [this guys probably is a short on onty but long PD-1 drug maker and he is anxious about the potential approval of BLP-25. He hope he is the guy sitting in FDA]
Details
H. Jack West, MD ‏@JackWestMD 52m
@ColfaxCapital agree on all counts. Scientific Qs independent of practical realities." [What a pathetic reply which even has nothing to reflect he is a doctor]

When WS is awaken, and realized it has not been in the position of significant shareholders, it manipulates. The same thing happens in MCP, BBRY until WS crooks have taken their positions. The share price could be at any levels.